Association of increased total antioxidant capacity and anovulation in nonobese infertile patients with clomiphene citrate-resistant polycystic ovary syndrome.
OBJECTIVE
To investigate whether total antioxidant capacity (TAC) could predict the response to ovulation induction to clomiphene citrate (CC) in nonobese women with polycystic ovary syndrome.


METHODS
Prospective longitudinal follow-up study.


METHODS
Academic hospital.


METHODS
Fifty-five nonobese, oligomenorrheic women with polycystic ovary syndrome and normal indices of insulin sensitivity.


METHODS
None.


METHODS
Standard clinical examinations and ultrasonographic and endocrine screening, including FSH, LH, E(2), P, total T, sex hormone-binding globulin, DHEAS, and TAC were performed before initiation of CC medication.


RESULTS
Within the total group, 27 (49%) of the patients did not ovulate at the end of follow-up. TAC, free androgen index, and ovarian volume were all significantly different in CC nonresponders from those in responders. Total antioxidant capacity was found to be the best predictor in univariate analysis (odds ratio, 171.55; 95% confidence interval, 10.61-2,772.93), and it had the highest area in the receiver operating characteristics analysis (0.91). In a multivariate prediction model, TAC, free androgen index, and ovarian volume showed good predictive power, with Hosmer-Lemeshow goodness of fit test of 0.80.


CONCLUSIONS
Total antioxidant capacity was the strongest predictor of ovarian response during CC induction of ovulation in these patients. It can be concluded that TAC can be used as a routine screening test.
Verit
Fatma Ferda
FF
Department of Obstetrics and Gynecology, Faculty of Medicine, Harran University, Sanliurfa, Turkey. fverit@harran.edu.tr <fverit@harran.edu.tr>
Erel
Ozcan
O
Kocyigit
Abdurrahim
A
D000328:Adult; D000858:Anovulation / Q000209:etiology*; D000975:Antioxidants / Q000502:physiology*; D015992:Body Mass Index; D002996:Clomiphene / Q000627:therapeutic use*; D004351:Drug Resistance / Q000502:physiology*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007247:Infertility, Female / Q000209:etiology*; D007333:Insulin Resistance; D008137:Longitudinal Studies; D010062:Ovulation Induction / Q000379:methods; D011085:Polycystic Ovary Syndrome / Q000150:complications / Q000188:drug therapy*; D020845:Selective Estrogen Receptor Modulators / Q000627:therapeutic use; D017211:Treatment Failure
D000975:Antioxidants; D020845:Selective Estrogen Receptor Modulators; D002996:Clomiphene